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ABSTRACT
Objective To test in West Africa the impact of rapid
diagnostic tests on the prescription of antimalarials and
antibiotics both where microscopy is used for the
diagnosis of malaria and in clinical (peripheral) settings
that rely on clinical diagnosis.
Design Randomised, controlled, open label clinical trial.
Setting Four clinics in the rural Dangme West district of
southern Ghana, one in which microscopy is used for
diagnosis of malaria (“microscopy setting”) and three
where microscopy is not available and diagnosis of
malaria is made on the basis of clinical symptoms
(“clinical setting”).
Participants Patients with suspected malaria.
Interventions Patients were randomly assigned to either a
rapid diagnostic test or the current diagnostic method at
the clinic (microscopyor clinical diagnosis).Abloodsample
for a research microscopy slide was taken for all patients.
Main outcome measures The primary outcome was the
prescription of antimalarials to patients of any age whose
double read research slide was negative for malaria. The
major secondary outcomes were the correct prescription
of antimalarials, the impact of test results on antibiotic
prescription, and the correct prescription of antimalarials
in children under 5 years.
Results Of the 9236 patients screened, 3452 were
randomised in the clinical setting and 3811 in the
microscopy setting. Follow-up to 28 days was 97.6%
(7088/7263). In the microscopy setting, 722 (51.6%) of
the 1400 patients with negative research slides in the
rapid diagnostic test arm were treated for malaria
compared with 764 (55.0%) of the 1389 patients in the
microscopy arm (adjusted odds ratio 0.87, 95%CI 0.71 to
1.1; P=0.16). In the clinical setting, 578 (53.9%) of the
1072 patients in the rapid diagnostic test arm with
negative research slides were treated for malaria
compared with 982 (90.1%) of the 1090 patients with
negative slides in the clinical diagnosis arm (odds ratio
0.12, 95% CI 0.04 to 0.38; P=0.001). The use of rapid
diagnostic tests led tobetter targeting of antimalarials and
antibiotics in the clinical but not themicroscopy setting, in
both children and adults. There were no deaths in children
under 5 years at 28 days follow-up in either arm.
ConclusionWhere microscopy already exists, introducing
rapid diagnostic tests had limited impact on prescriber
behaviour. In settings where microscopy was not
available, however, using rapid diagnostic tests led to a
significant reduction in the overprescription of
antimalarials, without any evidence of clinical harm, and
to better targeting of antibiotics.
Trial registration ClinicalTrials.gov NCT00493922.
INTRODUCTION
Falciparum malaria is one of the most important dis-
eases in Africa, both in terms of mortality and burden
on health services. Many people in Africa who have
malaria are not being treated with effective drugs.1
Simultaneously, a substantial proportion, sometimes
the majority, of those treated for malaria in both East
and West Africa are not actually infected with malaria
parasites.2-4 Given that malaria is the most common
diagnosis made in African children and one of the
most common in adults, both underdiagnosis and
overdiagnosis ofmalaria have substantial public health
implications. Missing true cases threatens the lives of
otherwise well children, whereas people wrongly trea-
ted formalaria often have alternative diagnoses—espe-
cially bacterial diseases, some of which are potentially
fatal—that are not being treated.5 6
Overdiagnosis also leads to overuse of antimalarial
drugs, potentially increasing the risk of spread of drug
resistant malaria. Given that the current highly effec-
tive drugs are substantially more expensive than pre-
vious antimalarials, the economic implications of
overdiagnosis are considerable and undermine the
cost effectiveness of the newer artemisinin based com-
bination therapies (ACTs).7Malaria incidence is falling
in some areas, and the problem of overtreatment
becomes more important where malaria incidence is
decreasing because the proportion of serious causes
of febrile illness that are not malaria increases.8 Over-
diagnosis of malaria is therefore likely to be an increas-
ing problem.
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Until recently, proper diagnosis of malaria relied on
light microscopy. This approach is possible or cost
effective only in settings with high throughput and
where trained microscopists are available.9 New
rapid diagnostic tests (RDTs) for falciparum malaria
are sensitive and specific (although there ismarkedvar-
iation between different makes of tests),10 11 and can be
used in peripheral settings (rural and community set-
tings) wheremost patients inAfrica get their care. They
do not require microscopes, electricity, or trained
laboratory staff. They are also potentially cost effec-
tive, but only if prescribers use the results to guide their
prescribing.12 Studies in central clinics in East Africa
where microscopy is used for diagnosis suggest that
clinicians often do not change their prescribing beha-
viour when given rapid diagnostic tests to use,13 14 and
one study indicated that rapid diagnostic tests even
have thepotential to beharmful by encouragingunder-
treatment of true malaria compared with presumptive
treatment.15 A good response to the results of rapid
diagnostic tests has, however, been achieved under
certain circumstances.16 17
Several major questions need to be answered about
how best to use rapid diagnostic tests for the manage-
ment of febrile illness in Africa. Themost important of
these questions relates to the role of rapid diagnostic
tests in settings where microscopy is not available,
because most children and adults in Africa seek care
in such settings. Inaccurate prescription of anti-
malarials is greater in such situations because causes
of febrile illness are difficult to differentiate clinically
in the absence of tests. Testing the impact of rapid diag-
nostic tests in this setting is therefore essential. There is
much hope, but limited evidence, that they will also
have an impact where microscopy is not available
because prescribers who have not become used to
ignoring microscopy results because microscopy is
not available may be much more likely to use rapid
diagnostic tests to guide diagnosis and treatment.Addi-
tionally, most published studies on the impact of rapid
diagnostic tests on management of febrile illness were
performed in East Africa, but the largest burden of feb-
rile diseases is in thepopulous countries ofWestAfrica,
where malaria epidemiology, clinical training, and the
structure of the health service are very different from in
East Africa. Finally, there are few follow-up data on
patients once they have left clinics, and one of the con-
cerns is that rapid diagnostic tests may lead to greater
mortality and morbidity because they lead to cases of
true malaria being missed.
We set out to study the impact of rapid diagnostic
tests on prescribing of antimalarials and antibiotics in
West Africa in two settings serving the same popula-
tion: one where microscopy is routinely available (to
allow comparison with previous studies) and the other
where microscopy is not available (peripheral clinics,
which are representative of the majority of clinics in
sub-Saharan Africa). Most deaths from malaria are in
children, but themajority of antimalarials in Africa are
consumed by adults, so we examined the impact in
both children and adults.
METHODS
The study was a randomised, controlled, open label
clinical trial carried out in the Dangme West district
of southern Ghana, a rural district with an estimated
population of about 130 000 living in scattered com-
munities of less than 2000 people. The district has
four health centres and six community based clinics.
There is one publicly owned laboratory based in
Dodowa Health Centre, Dodowa, and two privately
owned laboratories in twoother subdistricts.All health
facilitieswhere there are no laboratories rely on clinical
diagnosis. The district has no hospital.
In 2008, a total of 31 971 cases of malaria were
reported in all health facilities in the district, both pub-
lic and private, which accounted for approximately
41% of all reported attendances. Of these 31 971
cases, 7808 (24%) were in children less than 5 years of
age. A high proportion of these diagnoses were pre-
sumptive (that is, made without tests).
Setting
The trial was undertaken in four health facilities in the
district, one of which (Dodowa Health Centre) had
facilities for microscopy. The others, where the diag-
nosis was normally presumptive, included one clinic
that is privately owned. The Dodowa Health Centre
is subsequently referred to as the “microscopy setting,”
whereas the other health facilities as a group are
referred to as the “clinical setting.”
The healthcare professionals were mostly nurses
with two years of basic training followed by several
years of experience in hospitals, or nurses with three
Screened in setting with microscopy
(”microscopy setting”; n=5157)
Screened in setting with no microscopy
(”clinical setting”; n=4079)
Randomised in setting
without microscopy (n=3452)
Randomised in setting
with microscopy (n=3811)
Total screened (n=9236)
Microscopy
(n=1907)
Rapid diagnostic
test (n=1904)
Clinical diagnosis
(n=1727)
Rapid diagnostic
test (n=1725)
Followed up on
day 28 (n=1672)
Refused consent (n=2)
Did not meet inclusion criteria (n=148):
  Pregnant (n=3)
  Left area (n=144)
  Other (n=1)
Observational (repeat visits) (n=477) Observational (repeat visits) (n=832)
Lost to
follow-up (n=53)
Followed up on
day 28 (n=1676)
Lost to
follow-up (n=51)
Followed up on
day 28 (n=1867)
Lost to
follow-up (n=37)
Followed up on
day 28 (n=1873)
Lost to
follow-up (n=34)
Refused consent (n=52)
Did not meet inclusion criteria (n=462):
  Pregnant (n=10)
  Left area (n=450)
  Other (n=1)
  Pregnant and left area (n=1)
Trial profile for rapid diagnostic tests versus microscopy or clinical diagnosis in two settings in
Ghana
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years of basic training resulting in a diploma and
usually a number of years of experience in hospitals.
The healthcare professionals also included auxiliary
nurses with two years of basic training and additional
“on the job” training in basic curative care. The final
category of healthcare professionals was nurse practi-
tioners with three years of basic training resulting in a
diploma followed by an additional two years of train-
ing in curative care, often separated by a number of
years of work in hospitals and sometimes training in
midwifery. The latter group was the most highly
trained and experienced. There was only one doctor.
Before the study begun, all healthcare professionals
in participating centres were given identical training
about the sensitivity and specificity of rapid diagnostic
tests, alternative causes of febrile illness, and theGhana
national guidelines, which indicate presumptive treat-
ment for children under 5 years of age (that is, the treat-
ment is assignedwithout carrying out a diagnostic test).
The first day focused on differential diagnoses of fever
in children and adults, whereas the second day focused
on the study itself and rapid diagnostic tests. In the
training, emphasis was placed on the difference
between a diagnosis by microscopy, which depends
on identification of the malaria parasite, and a diagno-
sis according to the rapid diagnostic test, which relies
on an antigen-antibody reaction. This distinction was
emphasised to improve the perceptions of negative
clinical slide results among healthcare professionals.
The healthcare professionals were also trained to
carry out and interpret the rapid diagnostic test them-
selves. Theywere, however, left free tomake their own
clinical decisions after the initial training. The training
took two days and was designed to replicate the best
training that could reasonably be delivered in a routine
roll-out of rapid diagnostic tests.
Participants and randomisation
All patients visiting the health facilities were screened
for enrolment into the study. The inclusion criteria
were that the healthcare professional considered treat-
ing the patient for malaria and wanted to test for
malaria or treat the patient with an antimalarial. Exclu-
sion criteria were pregnancy, illness severe enough to
warrant referral to a hospital, insistence by the health-
care professional on a particular test or a particular
method of treatment, patient insistence on a particular
test, refusal of consent by the patient or guardian (for
minors), not living in the district or nearby, or not
intending to remain in the district for the next two
months for follow-up.
OptiMAL-IT rapid diagnostic test kits (DiamedAG,
Cressier sur Morat, Switzerland)18 were used for this
study. This test uses a dipstick coated withmonoclonal
antibodies against plasmodium lactate dehydrogenase,
which is released from erythrocytes infected with the
parasite. Local microscopy used Giemsa staining, with
the parasite count recorded as +, ++, or +++.
In both settings a blood sample for a research slide
was taken for all patients. Research slides wereGiemsa
stained and read by two independent microscopists
who were blind to the study allocations and results of
the rapid diagnostic tests. In cases where the two read-
ers had discordant results, the slide was read by a third
reader. These analyses by the expert microscopists
were undertaken later and not used by the healthcare
professionals in their treatment decisions.The research
slides were examined under 100× oil immersion mag-
nification and a film was recorded as positive or nega-
tive and parasite count recorded for malaria on the
basis of the number of asexual parasites per 200 white
blood cells.
Randomisation was carried out using Stata 8 soft-
ware (Statacorp, College Station, TX) by staff not
involved in clinical care. Randomisation was carried
out in blocks of 10 for each setting. The allocations
were placed in sealed, sequentially numbered, opaque
envelopes anddelivered to the study team.At all health
facilities, envelopes were arranged and allocated
sequentially.
Intervention
At the single health facility with microscopy facilities,
patients who fulfilled the inclusion criteria andwho the
health professional wished to have tested for malaria
were sent to a member of the study team, who carried
out an evaluation for eligibility and obtained informed
consent and demographic and clinical data. A sealed,
sequentially numbered envelope containing the
patient’s test allocation—either “rapid diagnostic test”
or “microscopy”—was opened in the presence of the
patient; this constituted entry to the trial and intention
to treat analysis was conducted on the basis of this allo-
cation. The allocated test, either rapid diagnostic test or
Table 1 | Baseline characteristics of patients randomly allocated to rapid diagnostic testing or to microscopy or clinical diagnosis
Health centre with microscopy (“microscopy setting”) Health facilities with no microscopy (“clinical setting”)
Rapid diagnostic test arm Microscopy arm Rapid diagnostic test arm Clinical diagnosis arm
Median age (months (IQR)) 14 (4 to 33) 13 (4 to 31) 12 (4 to 32) 12 (4 to 30)
Proportion female 1148/1904 (60.3) 1155/1907 (60.6) 1035/1725 (60.0) 999/1727 (57.9)
Proportion belonging to bottom two wealth quintiles
(out of study participants who were successfully followed up)
745/1867 (40.0) 734/1873 (39.0) 634/1672 (38.0) 687/1676 (41.0)
Median temperature °C (interquartile range) 36.5 (36 to 37.4) 36.5 (36 to 37.4) 37.2 (36.2 to 38.4) 37.2 (36.3 to 38.4)
Proportion with fever in past 48 hours 1018/1904 (53.5) 1002/1907 (52.5) 919/1725 (53.3) 937/1727 (54.3)
Proportion positive for malaria parasites on double read slide 498/1904 (26.2) 513/1907 (26.9) 651/1725 (37.7) 634/1727 (36.7)
Parasite count per μl (IQR) in slide positive patients 9200 (1620 to 34 640) 8000 (1360 to 27 200) 9680 (1500 to 28 760) 10 240 (1640 to 29 600)
Values given as number (percentage) unless otherwise indicated.
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local microscopy, was then carried out in the clinic’s
laboratory, with a separate research slide taken for all
cases to be read later. The laboratory results were writ-
ten out as usual in the case of clinical microscopy, and
rapid diagnostic test results were recorded and the dip-
stick sent in its case to the healthcare professional to
read as well.
At the three health facilities where microscopy was
not available, healthcare professionals sent patients in
whom they suspected malaria to the study team.
Informed consent was sought and eligible patients
were randomised in the same way as those at the clinic
with microscopy facilities. In the case of allocation to
the rapid diagnostic test group, the test was carried out
by a member of the study team and the results
recorded. The results were sent together with the
rapid diagnostic test kit to the healthcare professional
for clinician read diagnosis and subsequent treatment.
In cases where the patient was assigned to clinical diag-
nosis, the laboratory results formwith “clinical diagno-
sis” ticked on it was returned to the healthcare
professional. A blood sample for a research slide was
also taken—this was not read until later.
Outcome measures
The primary outcome was the proportion of patients,
either children or adults, who did not have malaria on
the basis of a negative double read research slide but
were prescribed antimalarial treatment.
Secondary outcomes included the proportion of
patients whose research slide was positive for malaria
and who were not prescribed an antimalarial, the pro-
portion of patients whose research slide was either posi-
tive or negative who were prescribed antibiotics, the
proportion of patients whose rapid diagnostic test result
was positive and who were not prescribed an anti-
malarial, and the composite measure of “correct pre-
scription of antimalarials,” meaning antimalarials
being given to all patients who were test positive and
not to anyone who was test negative, in all patients
and in children under 5 years only. The sensitivity and
specificity of rapid diagnostic tests were also calculated
against the double read research slides. The response of
healthcare professionals was measured objectively by
appropriate prescription of an effective antimalarial or
abroad spectrumantibiotic capableof treatingcommon
Gram positive or Gram negative pathogens (for exam-
ple, pneumococcus or non-typhoid salmonella).
Patients were followed up at their homes 28 days
after enrolment to determine subsequent treatment
seeking and any mortality or admissions to hospital,
and to confirm socioeconomic variables. A random
sample of 500 patients in both the clinical and micro-
scopy settings had blood films taken during follow-up.
Statistical analysis
Data were entered into Epi Info 6 (Centers for Disease
Control and Prevention, Atlanta, GA) and analysed
using Stata 10 (Statacorp). Simple proportions were
calculated for the study groups overall, and then results
were stratified by age. In all cases results from the
microscopy setting and those from the clinical setting
were analysed separately. For the primary and major
secondary outcomes, odds ratios were calculated in an
uncorrected logistic regression model and subse-
quently adjusted for age, sex, socioeconomic status,
and clustering by healthcare professional. Socioeco-
nomic status was determined by constructing an asset
index, which has been validated locally, and calculat-
ing quintiles.19 Clustering by healthcare professional
was adjusted for by using the “svy” command in
Stata, with healthcare professionals as the primary
sampling unit.
The sample size was calculated to allow us to detect a
25% reduction in overprescription of antimalarials in
patients of any age in the microscopy and clinical set-
tings independently (α=0.05, β=0.8); a reduction less
than this was thought unlikely to lead to a public health
change as large and potentially expensive as deploying
rapid diagnostic tests. Published studies suggest that an
antimalarial will be prescribed in at least 45% of
patients who have a negative blood slide result, where
microscopy is present. The primary outcomewas over-
prescription irrespective of age in each setting indepen-
dently (that is, both in the clinical setting and the
microscopy setting), but we wished to have power for
amajor secondary analysis restricted to children, so the
trial was powered for this analysis (and, therefore, over-
powered for the primary analysis). We assumed on the
basis of previous clinic data that the ratio of patients in
whommalaria was suspected would be 2:1 for children
to adults. In adults we conservatively estimated that
overprescription would be 50%. In children we
Table 2 | Antimalarial and antibiotic prescribing behaviour measured against the double read research slides*
Health centre with microscopy
(“microscopy setting”)
Health facilities with no microscopy
(“clinical setting”)
Rapid diagnostic
test arm
Microscopy
arm
Rapid diagnostic
test arm
Clinical diagnosis
arm
Proportion of patients with a positive research slide treated with antimalarials 462/496 (93.2) 458/511 (89.6) 626/647 (96.8) 616/633 (97.3)
Proportion of patients with a negative research slide treated with antimalarials 722/1400 (51.6) 764/1389 (55.0) 578/1072 (53.9) 982/1090 (90.1)
Proportion of patients with a positive research slide treated with antibiotics 67/496 (13.5) 67/511 (13.1) 87/647 (13.4) 102/633 (16.1)
Proportion of patients with a negative research slide treated with antibiotics 374/1400 (26.7) 383/1389 (27.6) 370/1072 (34.5) 282/1090 (25.9)
Correct treatment of malaria 1140/1896 (60.1) 1085/1900 (57.1) 1123/1719 (65.3) 724/1723 (42.0)
Values given as number (percentage) unless otherwise indicated.
*Nineteen participants did not have information on the diagnosis or prescription written by the healthcare professional in their records and records for six patients were missing, so these
individuals were excluded from the analyses.
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estimated it would be 30%. Detecting a 25% reduction
in overprescription required a sample size of 2500 chil-
dren and 1000 adults, or 3500 patients overall for the
microscopy setting. In the clinical setting, we estimated
that the overprescription of antimalarials was likely to
be 10%higher in both children and adults; thus around
3000 patients were required. The total required sample
size for the whole study was therefore 6500.
This trial was prospectively registered at Clinical-
Trials.gov as NCT00493922.
RESULTS
The trial ran from 6 August 2007 to 24 December
2008. Of the 9236 patients screened, 3452 were rando-
mised in the clinical setting (1725 patients to the rapid
diagnostic test and 1727 to clinical diagnosis) and 3811
in the microscopy setting (1904 patients to the rapid
diagnostic test and 1907 to microscopy). Final data
for the primary outcome were not available in nine
patients whose records were lost (0.1%). A total of
175 patients (2.41%) were lost to follow-up, with no
obvious difference between those lost and the rest of
the study group.
There were a total of 16 and 13 prescribers in the
microscopy and clinical settings, respectively, over
the period of the study. Three healthcare professionals
were transferred out of the district, one of whom
retired, and two new health professionals, including a
doctor, were transferred in during the latter part of the
study. The median number of patients seen was 121
(range 3 to 1450). The highest number was by the
sole healthcare professional at the private clinic with-
out microscopy.
The figure shows the flow of patients through the
trial, and baseline characteristics of the randomised
patients in the two settings are shown in table 1.
Judged against the diagnoses according to the dou-
ble read research slide, rapid diagnostic tests did not
lead to a reduction in incorrect prescribing of anti-
malarials in the microscopy setting, or to a change in
antibiotic prescribing. The proportion of patients with
a negative research slide wrongly treated with anti-
malarials was 51.6% (722/1400) in the rapid diagnostic
test arm and 55.0% (764/1389) in the microscopy arm
(odds ratio (OR) 0.88, 95% CI 0.75 to 1.02; table 2).
There was likewise no difference in prescribing once
the analysis was adjusted for the predefined potential
confounding factors of age, sex, socioeconomic status,
and clustering by healthcare professional (adjustedOR
0.87, 95%CI 0.71 to 1.1; P=0.16). Among patients with
a positive research slide, 6.9% (34/496) in the rapid
diagnostic test arm were not treated for malaria com-
pared with 10.4% (53/511) in themicroscopy arm. The
odds ratio of rapid diagnostic tests leading to better tar-
geting of antimalarials in the microscopy setting—
defined as all individuals positive formalaria according
to their research slide being treated for malaria and all
negative cases not being treated—was 1.1 (95%CI 0.99
to 1.3, P=0.05; adjusted OR 1.2, 95% CI 0.94 to 1.4).
There was no evidence of clustering by healthcare pro-
fessional having more than a minor effect. Rapid diag-
nostic tests had no clinically relevant impact on
antibiotic prescribing in this setting: 23.3% (441/1896)
in the rapid diagnostic test arm and 23.7% (450/1900)
in the microscopy arm were treated with antibiotics.
On the other hand, rapid diagnostic tests had a sig-
nificant impact on the accuracy of prescribing in the
clinical setting (where microscopy was not available).
The proportion of patients with negative research
slides wrongly treated with antimalarials was 53.9%
(578/1072) in the rapid diagnostic test arm compared
with 90.1% (982/1090) in the clinical diagnosis arm
(OR 0.13, 95% CI 0.01 to 1.6; adjusted OR 0.12, 95%
CI 0.04 to 0.38; P=0.001). The proportion of patients
with a positive slide not treated for malaria was similar
in the two arms: 2.7% (17/633) in the clinical arm and
3.2% (21/647) in the rapid diagnostic test arm. The
odds ratio of rapid diagnostic tests leading to better
targeting of antimalarials in this setting was 2.6 (95%
CI 2.2 to 3.0). When adjusted for age, sex, socioeco-
nomic status and clustering by healthcare professional,
Table 3 |Antimalarial and antibiotic prescribing in patients randomly allocated to rapid diagnostic testing or clinical diagnosis in health facilities with no
microscopy and in patients assigned rapid diagnostic testing or microscopy in a health centre with microscopy*
Health centre with microscopy
(“microscopy setting”)
Health facilities with no microscopy
(“clinical setting”)
Rapid diagnostic
test arm
Microscopy
arm
Rapid diagnostic
test arm
Clinical diagnosis
arm
Proportion of patients treated with antimalarials only 1018/1896 (53.7%) 1038/1900 (54.6%) 993/1719 (57.8%) 1268/1723 (73.6%)
Proportion treated with antibiotics only 275/1896 (14.5%) 267/1900 (14.1%) 246/1719 (14.3%) 54/1723 (3.1%)
Proportion treated with both antimalarials and antibiotics 166/1896 (8.8%) 183/1900 (9.6%) 211/1719 (12.3%) 330/1723 (19.2%)
Proportion of patients with a positive rapid diagnostic test or clinic microscopy result
treated with antimalarials
587/598 (98.2%) 565/575 (98.3%) 703/706 (99.6%) NA
Proportion of patients with a negative rapid diagnostic test or clinic microscopy
result treated with antimalarials
597/1298 (46.0%) 656/1325 (49.5%) 501/1013 (49.5%) NA
Proportion of patients with a positive rapid diagnostic test or microscopy result
treated with antibiotics
67/598 (11.2%) 71/575 (12.3%) 102/706 (14.4%) NA
Proportion of patients with a negative rapid diagnostic test or microscopy result
treated with antibiotics
374/1298 (28.8%) 379/1325 (28.6%) 355/1013 (35.0%) NA
*Nineteen participants did not have information on the diagnosis or prescription written by the healthcare professional in their records and records for six patients were missing, so these
individuals were excluded from the analyses.
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the odds ratio increased to 2.7 (95% CI 1.1 to 6.5;
P=0.03).
Judged against the test result available to the health-
care professional rather than the double read slide, in
the microscopy setting there was no clinically relevant
difference in the overall prescription of either anti-
malarials or broad spectrum antibiotics between the
rapid diagnostic test arm and the microscopy arm.
The similarities between the two study arms held
whether test results available to healthcare profes-
sionals were positive or negative and in all age groups
(tables 3 and 4). Of those patients who had malaria
according to the test results available to healthcare pro-
fessionals, 98.2% (587/598) in the rapid diagnostic test
arm and 98.3% (565/575) in the microscopy arm were
treated. Only 1.2% (11/598) of those in the rapid diag-
nostic test armwithmalariawere not treated compared
with 1.7% (10/575) in the microscopy arm, and all
these individuals were all aged more than 15 years.
This finding suggests that rapid diagnostic tests did
not lead to underprescription of antimalarials as com-
pared with microscopy. Of the 1184 patients in the
rapid diagnostic test group given an antimalarial, in
50.4% (597 cases) of participants the prescriber had
recorded that the result was negative.
By contrast, when prescribing in the clinical setting
was compared with the healthcare professionals’ inter-
pretation of the rapid diagnostic test, there were still
significant differences in the prescription of anti-
malarials and antibiotics between the rapid diagnostic
test and clinical diagnosis arms.A total of 92.8% (1598/
1723) of patients in the clinical diagnosis armwere pre-
scribed antimalarials compared with 70.0% (1204/
1719) of patients in the rapid diagnostic test arm (OR
0.18, 95%CI 0.15 to 0.22; P<0.001; table 3). Prescrib-
ing of antibiotics was 22.3% (384/1723) in the clinical
diagnosis arm and 26.6% (457/1719) the rapid diag-
nostic test arm (OR 1.3, 95% CI 1.08 to 1.5;
P=0.003). Healthcare professionals in the clinical set-
ting respondedmore logically to positive and negative
rapid diagnostic test results available to them than did
professionals in the microscopy setting: the former
were less likely to prescribe an antimalarial to a patient
who had a negative test result. Of the 1204 people in
the rapid diagnostic test group given an antimalarial,
41.6% (501 cases) had a negative result on the test.
We also compared participants who had a fever or
history of fever with those who did not. In the fever
group, 51% (560/1098) in the clinical diagnosis arm
and 70% (761/1092) in the rapid diagnostic test arm
were correctly prescribed antimalarials (P<0.001). In
the group without fever or history of fever, 26% (164/
623) in the clinical diagnosis arm and 57% (361/628) in
the rapid diagnostic test armwere correctly prescribed
antimalarials. Rapid diagnostic tests, therefore, made a
clinically and statistically significant difference in the
correct prescription of antimalarials in both febrile
and non-febrile patients.
A further analysis restricted to children under 5 years
of age was undertaken. In the microscopy setting, 59%
(234/569) of children randomised to microscopy were
correctly prescribed antimalarials, compared with 60%
(345/570) of children randomised to rapid diagnostic
tests (OR 1.07, 95% CI 0.8 to 2.4; P=0.57). In the clin-
ical setting, 67% (348/520) of children randomised to
clinical diagnosis were correctly prescribed anti-
malarials, compared with 60% (225/570) randomised
to rapid diagnostic tests (OR 1.7, 95% CI 1.3 to 2.2;
P<0.001). The impact of antibiotic prescribing has the
potential to have an effect on children less than1yearof
age. In the microscopy setting, 40.2% (35/87) of chil-
dren under 1 year of age in the microscopy arm and
40.6% (41/101) in the rapid diagnostic test arm were
prescribed an antibiotic (OR 1.01, 95% CI 0.57 to
1.8). In the clinical setting, 29.3% (17/58) of children
under 1 year of age in the clinical arm and 41.0%
Table 4 | Antimalarial and antibiotic prescribing by age group in patients randomly allocated to rapid diagnostic testing or
clinical diagnosis in health facilities with no microscopy and in patients assigned rapid diagnostic testing or microscopy in
a health centre with microscopy*
Health centre with microscopy
(“microscopy setting”)
Health facilities with no microscopy
(“clinical setting”)
Rapid diagnostic test arm Microscopy arm Rapid diagnostic test arm Clinical diagnosis arm
Treated with antimalarials
Up to 1 year 57/101 (56.4) 50/87 (57.5) 45/61 (73.8) 51/58 (87.9)
1-5 years 330/469 (70.4) 343/482 (71.2) 370/458 (80.8) 458/492 (93.1)
5-15 years 329/442 (74.4) 344/475 (72.4) 356/422 (84.4) 391/410 (95.4)
16-70 years 427/787 (54.3) 444/767 (57.9) 401/719 (55.8) 647/707 (91.5)
70 years or above 41/97 (42.3) 40/89 (44.9) 32/59 (54.2) 51/56 (91.1)
Treated with antibiotics
Up to 1 year 41/101 (40.6) 35/87 (40.2) 25/61 (41.0) 17/58 (29.3)
1-5 years 117/469 (25.0) 119/482 (24.7) 126/458 (27.5) 140/492 (28.5)
5-15 years 85/442 (19.2) 88/475 (18.5) 91/422 (21.6) 77/410 (18.8)
16-70 years 181/787 (23.0) 187/767 (24.4) 201/719 (28.0) 144/707 (20.4)
70 years or above 17/97 (17.5) 21/89 (23.6) 14/59 (23.7) 6/56 (10.7)
Values given as number (percentage) unless otherwise indicated.
*Nineteen participants did not have information on the diagnosis or prescription written by the healthcare professional in their records and records
for six patients were missing, so these individuals were excluded from the analyses.
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(25/61) in the rapid diagnostic test armwere prescribed
an antibiotic (OR 1.67, 95% CI 0.8 to 3.6).
Judged against the results of the double read research
slides, the operational sensitivity of the rapid diagnos-
tic tests was 86.9% (433/498) in the microscopy setting
and 93.1% (606/651) in the clinical setting; the specifi-
city of rapid diagnostic tests was 88% (1242/1406) and
90.1% (969/1076), respectively. By contrast, the opera-
tional sensitivity of local microscopy used by health-
care professionals was 61.6% (316/513) and the
specificity 81% (1033/1395) judged against the double
read research slides. Sensitivity and specificity of rapid
diagnostic tests were therefore both higher than rou-
tine microscopy under operational conditions.
By day 28, 10 patients in the trial had died: all were
over 5 years of age. One child aged 11 years rando-
mised to microscopy died after reporting extreme
pain in the leg. The other nine deaths were in adults,
four of whom were individuals aged more than
60 years. In the clinical setting, four people in the clin-
ical arm and none in the rapid diagnostic test arm died.
In the microscopy setting, two patients in the micro-
scopy arm and four in the rapid diagnostic test arm
died. Malaria was mentioned as a possible cause of
death in two patients; one was 72 and the other
80 years old.One of these individuals had been treated
with artemisinin based combination therapy. In the
clinical setting, 266 (15.9%) patients randomised to
rapid diagnostic tests and 280 (16.8%) randomised to
clinical treatment sought further treatment of any sort.
Some studies have suggested that initial poor
response to new diagnostic methods improves with
time. Our study shows that in both study settings
there was an initial improvement in the correct pre-
scription of antimalarials after the first three months,
but that this was not sustained (table 5).
DISCUSSION
In common with a similar study in East Africa, in this
West African setting rapid diagnostic tests for malaria
had no impact on the prescription of antimalarials in
clinics where microscopy was available. Healthcare
professionals treated the results from rapid diagnostic
tests the same way as those from microscopy, often
ignoring negative results and prescribing antimalarials
regardless; the non-significant trend towards lower
prescription of antimalarials to patients whose double
read research slide was negative was because the
operational sensitivity of rapid diagnostic tests was
higher than that for routine microscopy.
On the other hand, in clinics where microscopy was
not available and normal practice was presumptive
treatment, which is typical of the majority of clinics in
sub-Saharan Africa, providing rapid diagnostic tests
had a clinically important impact on reducing overpre-
scription of antimalarials. The use of rapid diagnostic
tests also improved the targeting of antibiotics to
patients who did not have malaria according to their
double read research slide. There was no difference
between the rapid diagnostic test arm and the clinical
diagnosis arm in the proportions of cases of confirmed
malaria that were not treated, nor evidence that intro-
ducing antimalarial treatment targeted by rapid diag-
nostic tests where treatment is presumptive increased
mortality in children or care seeking 28 days later.
Despite these encouraging results in the clinical setting,
a substantial proportion of the artemisinin based com-
bination therapy prescribed when healthcare profes-
sionals had requested a test was still to patients with a
negative test result. Simply deploying rapid diagnostic
tests with a limited training package is unlikely to lead
to them having their full potential impact even in set-
tings where microscopy is not available.
Major efforts are being made by the Global Fund
and other organisations to increase the availability
and lower the cost of antimalarials.20 The public health
impact of these endeavours could be substantially
undermined in West Africa, where a large proportion
of the world’s deaths from falciparum malaria occur,
unless better targeting can be achieved. This is made
more urgent by the fact that malaria makes up a
decreasing proportion of febrile illness in some
areas.8 The emerging resistance to artemisinin based
regimens in Asia, from where previous antimalarial
drug resistance has spread, probably makes it more
likely that indiscriminate use of antimalarials will
speed up the spread of drug resistance.21 Giving anti-
malarials to people who do not have malaria has no
positive effect, and many alternative causes of febrile
illness are potentially being missed as a result of over-
diagnosis.
Comparison with other studies
Attempts to change practice in West Africa by imple-
menting rapid diagnostic tests have been disappoint-
ing, with more than 80% of patients whose rapid
diagnostic test was negative prescribed antimalarials
in one study.22 Changing the behaviour of prescribers
can be difficult in any setting where healthcare profes-
sionals are used to a particular prescribing pattern for a
common syndrome,23 as the prolonged efforts to
reduce unnecessary antibiotic prescribing in the UK
have demonstrated. The reasons malaria is overdiag-
nosed are complex.24
The disappointing results in the microscopy setting
are consistent with studies fromEast Africa.12 13 Micro-
scopy is more cost effective than rapid diagnostic tests
Table 5 | Incorrect prescription* of antimalarials in response
to the result of rapid diagnostic tests over time
Health centre
with microscopy
Health facilities
with no microscopy
Time period 1† 248/531 (46.8) 103/347 (29.6)
Time period 2† 45/186 (24.2) 48/274 (17.5)
Time period 3† 76/368 (20.7) 59/256 (23.1)
Time period 4† 149/591 (25.2) 197/570 (34.6)
Time period 5† 91/223 (40.8) 97/279 (34.8)
Values given as number (percentage) unless otherwise indicated.
*Incorrect prescription defined as antimalarials given to those with a
negative result on the rapid diagnostic test or withheld from those with a
positive result on the rapid diagnostic test.
†Each time period was around 100 days.
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in settings where there is high throughput. Therefore,
improving existingmicroscopy techniques should ide-
ally be the aim in these settings because there is no
evidence that substituting rapid diagnostic tests has
any advantages on prescribing behaviour. The opera-
tional sensitivity of microscopy was low in our study,
however, and sustaining improvements in laboratory
standards can be challenging25; rapid diagnostic tests
may therefore have a role in quality control. As
shown by this study and other trials of rapid diagnostic
tests where microscopy is the comparator,26 27 improv-
ing diagnostic techniqueswith targeted training cannot
be assumed to translate into better diagnosis for
patients. Strenuous efforts will be needed to under-
stand, and change, existing clinical behaviour where
healthcare professionals have got used to ignoring
negative malaria tests.
There are several reasons healthcare professionals
and public health officials in Africa have been cautious
about introducing rapid diagnostic tests in peripheral
settings, where this study suggests they do lead to
changes in prescribing. Two are addressed by this
study directly. The first is that because rapid diagnostic
tests do not have an impact on prescribing where
microscopy is available, people feel that there is no
point using them. However, in this setting at least,
introducing rapid diagnostic tests had a much greater
impact on promoting rational prescribing of anti-
malarials and antibiotics where there was no existing
microscopy than where microscopy was available.
The second is the concern that truemalaria caseswill
be missed when rapid diagnostic tests are used, and
that this will lead to harm. There was, however, no evi-
dence in this study that the reduction of overdiagnosis
was balanced by an increase in underdiagnosis, or that
rapid diagnostic tests led to an increase in repeat atten-
dance or mortality at 28 days. The study was not pow-
ered to detect a difference in mortality though, so this
finding should be interpreted with caution.
One real concern could not be dealt with: that
deploying a blood test where it has not been used
before is not risk-free in settings where the prevalence
of blood borne viruses is relatively high. Additionally,
although it is logical to assume that improving target-
ing of antibiotics to children who do not have malaria
according to their research laboratory slide should
have an impact on reducing subsequent severe bacter-
ial illness,28 direct evidence for this is currently lacking.
Limitations of the study
The major weakness of all studies of patient and pre-
scriber behaviour are that behaviour cannot automati-
cally be generalised from one setting to another. This
study is no exception, although it is reassuring scienti-
fically, if not in public health terms, that our results are
consistent with data from East Africa that show a lim-
ited impact of rapid diagnostic tests where microscopy
exists. This agreement strengthens the likelihood that
the positive impact we recorded in a community set-
ting is in fact a real and generalisable effect. Addition-
ally, there is always the risk that being in a trialwill itself
change the behaviour of healthcare professionals (the
Hawthorne effect).
Much of the difference between previous studies has
been assumed to be due to different training packages
and diagnostic settings; in this study, prescribers in
both the clinical setting and the microscopy setting
were given identical training together, used the same
test, and were in the same catchment area. Although
residual differences in both caseload and prescriber
behaviour will exist, the impact of rapid diagnostic
tests was very different in the two settings. In general,
the operational effectiveness of any intervention when
used in normal practice is lower than that found in
research studies, even in pragmatic trials.
Conclusion
The role of rapid diagnostic tests for the treatment of
malaria is the subject of considerable debate.2930 This
studyprovides evidence to support exploring thedeploy-
ment of rapid diagnostic tests for malaria in West Africa
in settings wheremicroscopy is not available. The results
also show that wheremicroscopy is available, rapid diag-
nostic tests are unlikely to have more than a marginal
impact on existing prescriber behaviour if deployed
with a pragmatic training package.
Using rapid diagnostic tests is, however, likely to
achieve its greatest impact only if accompanied by
training and supervision tailored to the users and
informed by social science studies. Although the
impact of rapid diagnostic tests on prescriber beha-
viour in settings where diagnosis is currently syndro-
mic (based on symptoms) is encouraging, for malaria a
substantial proportion of negative tests by any techni-
que are still ignored. This problem will need to be
tackled if treatment according to rapid diagnostic
tests is to be more effective and cost effective than pre-
sumptive treatment. While we acknowledge the lim-
ited generalisability, our study provides support for
the deployment of rapid diagnostic tests in peripheral
settings where microscopy is not available.
WHAT IS ALREADY KNOWN ON THE TOPIC
Malaria is massively overdiagnosed in Africa, but at the same time true cases being are
missed
In East Africa, introducing rapid diagnostic tests for malaria in clinics where microscopy is
available has had a disappointing effect on prescribing in many settings
Most people in Africa seek care in peripheral clinics where microscopy is not available
WHAT THIS STUDY ADDS
In West Africa, the use of rapid diagnostic tests substantially reduced the overprescription of
antimalarials in settings where malaria was diagnosed clinically (without microscopy, the
most common situation)
Rapid diagnostic tests also led to better targeting of antibiotics in settings where microscopy
was not available
Rapid diagnostic tests had limited impact on prescription of antimalarials or antibiotics in
settings with microscopy facilities
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